J

Johnson & Johnson

Global healthcare company offering pharma, devices.

Forward Deployed Engineer Manager

Full-TimeUpdated on 10/2/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
HybridHybrid work in Hyderabad is required.

About the job

Requirements
  • Hands-on experience with AWS and Google Cloud Platform cloud services, including compute, storage, networking, security, data platforms, artificial intelligence and machine learning services, and observability capabilities.
  • Strong experience delivering enterprise-grade artificial intelligence and machine learning solutions using modern cloud architecture patterns within large, global technology organizations.
  • Deep understanding of microservices, containers, Kubernetes, serverless, event-driven architecture, application programming interface-based integration, data lake and lakehouse architectures, and distributed processing.
  • Strong understanding of the artificial intelligence and machine learning lifecycle, including data preparation, feature engineering, model training, model evaluation, deployment, monitoring, retraining, and governance.
  • Experience designing Generative AI solutions using large language models, Retrieval-Augmented Generation, vector search, semantic search, enterprise knowledge retrieval, and knowledge graph-based architectures.
  • Hands-on knowledge of Agentic AI architecture, including agent frameworks, multi-agent orchestration, autonomous workflow design, tool use, planning patterns, guardrails, and enterprise integration.
  • Strong understanding of prompt engineering, prompt lifecycle management, prompt evaluation, reusable prompt patterns, and operational controls for Generative AI applications.
  • Knowledge of DevOps practices and tools, including continuous integration and continuous delivery pipelines, Git-based workflows, automated deployments, infrastructure as code, containerization, and environment management.
  • Experience with MLOps concepts and tooling for automated model deployment, model registries, experiment tracking, model monitoring, and drift detection.
  • Ability to design secure, compliant, and resilient cloud solutions with identity and access management, encryption, network controls, logging, and auditability.
  • Knowledge of AI governance practices, including responsible AI implementation, AI risk assessment, model explainability and transparency, human-in-the-loop controls, validation, monitoring, and regulatory readiness.
  • Demonstrated ability to work in forward-deployed or embedded engineering models, including rapid discovery, solution shaping, prototyping, user validation, production delivery, and adoption support.
  • Bachelor’s or Master’s degree in Computer Science, Engineering, Data Science, Information Technology, or a related discipline.
  • At least 10 years of overall technology experience, including significant experience in hands-on engineering, solution architecture, cloud platforms, data engineering, artificial intelligence and machine learning, Generative AI, or enterprise solution delivery.
  • At least 10 years of experience designing and implementing cloud-native solutions on AWS, Google Cloud Platform, or multi-cloud environments.
  • Prior experience leading hands-on solution delivery, architecture discussions, design reviews, technical roadmaps, minimum viable product development, and cross-functional delivery teams.
  • Ability to operate effectively in ambiguous business environments and convert user needs into scalable technical solutions.
  • Strong stakeholder management and communication skills, including the ability to explain complex architecture decisions to technical and business audiences.
Responsibilities
  • Partner with business, product, clinical, scientific, data science, engineering, and technology stakeholders to identify high-impact use cases and translate them into deployable artificial intelligence, machine learning, and Generative AI solutions.
  • Rapidly prototype, validate, iterate, and deploy AI-enabled products, workflows, and platform capabilities with users and delivery teams.
  • Design scalable and reusable cloud architecture patterns across AWS and Google Cloud Platform, including serverless, containerized, microservices-based, event-driven, data lake, lakehouse, and hybrid cloud patterns.
  • Design and implement Generative AI solutions using large language models, Retrieval-Augmented Generation, semantic search, knowledge graphs, and enterprise knowledge integration.
  • Architect Agentic AI solutions, including autonomous AI workflows, multi-agent orchestration, agentic frameworks, tool integration, guardrails, and human-in-the-loop controls.
  • Embed with global product, data science, engineering, security, infrastructure, architecture, and business teams to convert ambiguous business requirements into secure, scalable, production-ready technical solutions.
  • Evaluate and recommend cloud-native AI and machine learning services, data platforms, compute options, integration patterns, and automation frameworks aligned with enterprise architecture standards.
  • Establish prompt engineering, prompt management, evaluation, versioning, reuse, and lifecycle practices for scalable Generative AI delivery.
  • Ensure architecture decisions meet performance, reliability, scalability, security, privacy, compliance, cost optimization, and operational resilience requirements in a regulated healthcare environment.
  • Provide hands-on technical leadership to engineering teams through implementation support, reference architectures, design reviews, code-level guidance, and technical standards.
  • Drive adoption of DevOps and MLOps practices, including continuous integration and continuous delivery, infrastructure as code, automated testing, model deployment automation, monitoring, alerting, and release governance.
  • Collaborate with governance, privacy, cybersecurity, quality, and compliance stakeholders to align AI and machine learning solutions with enterprise standards and regulatory expectations.
  • Implement responsible AI and AI governance practices, including AI risk assessments, model explainability, transparency, validation, monitoring, and regulatory readiness.
  • Support solution roadmaps, technology evaluations, proofs of concept, minimum viable product delivery, user feedback cycles, production rollout, and modernization initiatives.
  • Act as a technical partner for stakeholders by bridging strategy, architecture, engineering execution, adoption, and measurable business outcomes.
Desired Qualifications
  • Experience in clinical development, pharmaceutical research and development, healthcare, life sciences, medical technology, or other regulated domains.
  • Understanding of clinical development workflows, clinical trial data, regulated data platforms, privacy requirements, GxP considerations, and compliance-driven technology delivery.
  • Experience with AWS services such as SageMaker, Lambda, Elastic Container Service, Elastic Kubernetes Service, S3, Glue, Redshift, Identity and Access Management, CloudWatch, and related data or AI and machine learning services.
  • Experience with Google Cloud Platform services such as Vertex AI, BigQuery, Cloud Storage, Google Kubernetes Engine, Cloud Run, Cloud Functions, Pub/Sub, Identity and Access Management, and Cloud Monitoring.
  • Exposure to data engineering platforms, lakehouse architectures, Databricks, Spark, orchestration tools, and modern analytics platforms.
  • Cloud or architecture certifications such as AWS Solutions Architect, AWS Machine Learning Specialty, Google Professional Cloud Architect, or Google Professional Machine Learning Engineer.
  • Prior experience working in an innovative pharmaceutical company in a research and development domain.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
  • TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
  • CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.

What critics are saying

  • Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
  • Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
  • AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.

What makes Johnson & Johnson unique

  • J&J has 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
  • CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.